Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy

Дата публикации: 19-08-2026 00:00:00

This secondary analysis of the HELIOS-B randomized clinical trial evaluates the prognostic significance of left atrial structure and function among patients with transthyretin amyloidosis with cardiomyopathy and assesses the effects of vutrisiran on these parameters.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Vutrisiran Treatment and Cardiac and Amyloid Changes on MRI	0	5.2	12-08-2026
2	Ventricular Fibrillation With Intravascular Lithotripsy	0	6.17	19-08-2026
3	Spectrum of Aldosteronism and Cardiovascular Outcomes	0	6.27	01-04-2026
4	Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease	0	8.74	28-07-2026
5	Data on PDE9 inhibition in HF mixed; more research planned	0	13.32	12-10-2026
6	Cardiotoxicity of Immune Checkpoint Inhibitors	0	8	01-10-2024
7	Winrevair safety in Group 2/3 PH similar to Group 1 PAH	0	12.83	16-10-2026
8	Circulation: Largest genetic and MRI study carried out to date rules out the existence of heart disease	0	7.03	03-08-2026
9	Mobile Integrated Health and Post–Hospital Discharge Heart Failure Care	0	5.02	21-08-2026
10	Nature Cardiovascular Research: Researchers uncover a new mechanism underlying the most common inherited heart disease and confirm the effectiveness of a next-generation therapy	0	5.75	06-07-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.14. Источник: jamanetwork.com.